Jeffrey James Olson

Jeffrey James Olson is a Professor of Neurosurgery and Director of the Neuro-Oncology Program at Emory University's Winship Cancer Institute, where he has built one of the leading brain tumor programs in the southeastern United States. While trained as a neurosurgeon, Olson has dedicated his career to the multidisciplinary management of primary and metastatic brain tumors, with a particular expertise in optimizing the integration of surgical resection, radiation therapy, and systemic agents for glioblastoma and brain metastases. He has been a leading voice in developing evidence-based guidelines for the radiotherapeutic management of intracranial tumors. Olson served as the lead author or co-author of multiple ASTRO guideline documents and systematic evidence reviews covering brain metastases, low-grade glioma, high-grade glioma, and meningioma. His contributions to these guidelines involved systematic appraisal of randomized trial evidence and meta-analyses to produce consensus statements that directly influence radiation oncology clinical practice across North America. He has been deeply involved in cooperative group trials through NRG Oncology and has participated in the design of pivotal phase III trials evaluating whole-brain radiotherapy versus stereotactic radiosurgery, and the role of temozolomide-radiation combinations in newly diagnosed and recurrent glioblastoma. Beyond guidelines work, Olson has led translational research efforts examining the molecular determinants of radiation sensitivity in glioblastoma, including the roles of MGMT promoter methylation status and IDH mutation in predicting treatment benefit. His laboratory has investigated novel radiosensitizing strategies including targeted kinase inhibitors and anti-angiogenic agents. He is recognized for his ability to synthesize complex clinical and biological evidence into actionable treatment recommendations that improve outcomes for patients with brain tumors.